Search Results

On June 2nd, Daewoong Pharmaceutical (CEO Jeon Sengho, Lee Changjae) today announced that it and Neurogastrx have agreed to terminate the June 2021 license agreement, which granted Neurogastrx exclusive right to develop and commercialize Fexuprazan with respect to the U.S. and Canada market.

Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal disorders, announced the successful completion of a $60 million Series B crossover round led by Vivo Capital.

Neurogastrx, Inc., announced today that it has entered into an exclusive license agreement with Daewoong Pharmaceutical Co., Ltd., of Seoul, South Korea, for the development and commercialization of fexuprazan, an investigational novel potassium-competitive acid blocker (P-CAB) for the treatment of erosive esophagitis (EE) and other acid-related conditions.

The Series A financing was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners.

Jasper Therapeutics, Inc. today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations leadership teams.

Aura Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Westlake Village BioPartners announced the launch of its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond.